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Abstract
The interleukin-10 gene-deficient (Il10−/−) mouse is a model of human inflammatory bowel disease and
Ppara has been identified as one of the key genes involved in regulation of colitis in the bacterially
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relating to colitis severity. Actin cytoskeleton dynamics, innate immunity, and apoptosis-linked gene and
protein expression data suggested a delayed remodeling process in 12-week-old Il10−/− mice. Gene
expression changes in 12-week-old Il10−/− mice were related to PPARα signaling likely to control colitis,
but how PPARα activation might regulate intestinal IL10 production remains to be determined.
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The interleukin-10 gene-deficient (Il10−/− ) mouse is a model of human inflammatory bowel disease and Ppara has been identified
as one of the key genes involved in regulation of colitis in the bacterially inoculated Il10−/− model. The aims were to (1) characterize
colitis onset and progression using a histopathological, transcriptomic, and proteomic approach and (2) investigate links between
PPARα and IL10 using gene network analysis. Bacterial inoculation resulted in severe colitis in Il10−/− mice from 10 to 12 weeks
of age. Innate and adaptive immune responses showed diﬀerences in gene expression relating to colitis severity. Actin cytoskeleton
dynamics, innate immunity, and apoptosis-linked gene and protein expression data suggested a delayed remodeling process in
12-week-old Il10−/− mice. Gene expression changes in 12-week-old Il10−/− mice were related to PPARα signaling likely to control
colitis, but how PPARα activation might regulate intestinal IL10 production remains to be determined.

1. Introduction
The interleukin-10 gene-deficient (Il10−/− ) mouse is a wellestablished model of human inflammatory bowel disease
(IBD) and used to study the complex host-environment (e.g.,
diet, bacteria) interactions and the action of potential therapeutics [1]. Il10−/− mice develop a Crohn’s disease (CD)like colitis when exposed to commensal bacteria, whereas
no colitis is observed in the wildtype and germ-free Il10−/−
mice, which suggests an important role for IL10 in controling
tolerance towards commensal bacteria and in preventing
colitis in these mice [2, 3]. IL10 signals through Janus kinase

1/signal transducer and activator of transcription 3 and
p38 mitogen-activated protein kinase-dependent pathways
to induce suppressor of cytokine signaling-mediated [4] or
heme oxygenase 1-dependent [5] anti-inflammatory mechanisms. The immunopathology in Il10−/− mice represents a Thelper cell type 1 (Th1)- and Th17-polarized inflammation
with high colonic expression of interferon gamma (IFNγ) as
the main Th1-derived pro-inflammatory cytokine and IL17
[6, 7].
Both the severity and time-course of colitis in Il10−/−
mice are influenced by the inbred strain background when
maintained under the same conditions. The colitis in Il10−/−
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mice on the C57BL/6J background is mild to moderate
[6], compared with when the Il10 tm1Cgn allele is bred into
the 129/SvEv, C3H/HeJBir, or C3H.SW background strains,
where colitis is severe and progressive [8–10]. This suggests
that other genes or gene interactions particular to the genetic
background of each strain modify the development of colitis.
Intestinal inflammation also develops more consistently
when Il10−/− mice (C57BL/6J background) raised under
conventional conditions are inoculated with a mixture of
pure Enterococcus isolates (E. faecalis and E. faecium) alone,
or combined with conventional intestinal flora derived
from healthy C57BL/6J mice [11]. The timeline of colitis
development is unknown in these bacterially inoculated
Il10−/− (C57BL/6J) mice.
Studies to date have mostly applied transcriptomic [11–
14] and proteomic [15] methods separately to intestinal
tissue samples of various murine models of experimental
colitis and of IBD patients. It is important to integrate
gene and protein expression data to get a more comprehensive understanding of phenotypic changes. A previous
study showed that conventional non-inoculated Il10−/−
mice (C57BL/6J background) developed increasing colonic
inflammation, peaking at 12 weeks of age [16].
The first hypothesis of this study was that distinct gene
and protein expression patterns could be defined in noninflamed (7 weeks of age) and colitic (12 weeks of age)
Il10−/− mice. Since the time-course of colitis in the bacterially
inoculated Il10−/− mouse model (C57BL/6J background)
used by Roy et al. [11] is undefined, the first aim was to
characterize colitis onset and progression in this model and
to extend previous studies [11–15] by using a combined
histopathological, transcriptomic, and proteomic approach.
Gene network analysis identified the Ppara gene as one of
the key genes with decreased expression levels associated with
severe colitis when comparing bacterially inoculated Il10−/−
and C57 mice [17]. A critical role for PPARα in regulating
inflammation was first identified by Devchand et al. [18] who
observed a prolonged inflammatory response in Ppara−/−
mice. PPARα-ligands showed anti-inflammatory eﬀects in
experimental colitis including the Il10−/− mouse model [19,
20]. Based on these studies [17–20], the second hypothesis
was that PPARα and IL10 signaling pathways are interlinked
during colitis. The secondary aim was to investigate the
involvement of PPARα regulation in Il10−/− mice before and
after colitis onset using gene network analysis.

2. Methods and Materials
2.1. Animals and Induction of Colitis. A total of 30
male Il10−/− (C57BL/6J background, formal designation
B6.129P2-Il10<tm1Cgn>/J) and 30 male C57 control
(C57BL/6J) mice were obtained from The Jackson Laboratory (Bar Harbor, Maine, USA). For convenience and
consistency in reporting, their age was defined as 35 days or 5
weeks of age at the start of the study. Mice were individually
housed in standard shoebox size cages containing untreated
wood shavings (Hi Tech Security Disposals Ltd., Auckland,
New Zealand) and maintained under conventional condi-
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tions with a temperature of approximately 22◦ C, 50% relative
humidity, and a 12-hour light-dark cycle.
After 4 days, all mice were inoculated orally with a
mixture of pure E. faecalis and E. faecium strains and
complex intestinal flora derived from healthy C57BL/6J
mice raised under conventional conditions to obtain a
more consistent and reproducible intestinal inflammation, as
described previously [11].
2.2. Experimental Design. The objective of this experiment
was to study the onset and progression of colitis and associated changes in gene and protein expression in bacterially
inoculated Il10−/− mice as a model for future nutrigenomics
studies to explore the eﬀects of nutrition on IBD pathophysiology. Mice were randomly assigned to 5 sampling groups
(7, 8.5, 10, 12, and 14 weeks of age). The mice had free
access to water and were fed an AIN-76A standard powder
diet prepared in-house. The diet composition has been
described previously [11]. Throughout the experimental
period, dietary intake was estimated daily by weighing
uneaten food and adjusted to equal the mean amount of
food consumed by the Il10−/− mice on the previous day. All
mice were weighed thrice a week and carefully monitored for
disease symptoms (weight loss, soft feces, inactivity).
Tissue sampling was performed at 7, 8.5, 10, 12, and 14
weeks of age. Mice were euthanized by CO2 asphyxiation
and cervical dislocation, and cardiac puncture was then
performed. There was a fast-feed period prior to sampling as
described previously [17], and the intestine was isolated and
cut open lengthwise. One piece of each intact intestinal section (duodenum, jejunum, ileum, and colon) was stored at
room temperature in 10% phosphate-buﬀered formaldehyde
for histopathological assessment; another was immediately
frozen in liquid nitrogen and kept at −80◦ C for gene and
protein profiling.
2.3. Histology. The histopathological assessment of the full
thickness intestinal sections (duodenum, jejunum, ileum
or colon) and the scoring method have been described
previously [17]. This method produces a histological injury
score (HIS) for each sample. It is the sum (total HIS) of
principal histological aspects (inflammatory cell infiltration,
tissue destruction, and tissue repair). A total HIS score
of each intestinal section from 0–3 was regarded as no
inflammation, from 4–6 as moderate inflammation and ≥7
as severe inflammation.
2.4. RNA Isolation, Microarray Hybridization, and Analysis.
RNA isolation and microarray hybridization have been
described previously [17]. The microarray experiment used
15 arrays based on the histopathological assessment of the
colon: three colon samples of Il10−/− mice at 7 weeks of age
(no colitis), four of Il10−/− mice at 12 weeks of age (moderate
colitis), four of C57 mice at 7 weeks of age (no colitis),
and four of C57 mice at 12 weeks of age (no colitis). At 7
weeks of age, one Il10−/− mouse died of unknown causes
and two others were already showing moderate signs of colon
inflammation and were thus excluded. Each individual RNA
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sample was hybridized with a reference sample onto the
array. Array data were submitted to the Gene Expression
Omnibus, accession number GSE17990.
Statistical analysis and quality assessment of the microarray data were performed using linear models for microarray
analysis (limma) within the Bioconductor framework as
described previously [17]. All arrays passed the quality
control and were included in the analyses. Intensity ratios
for all microarray spots were normalized using a local
linear regression analysis (LOESS) to remove the eﬀect of
systematic variation in the microarrays and no background
correction was necessary due to homogeneous hybridization.
The normalized array data of each time point were log2 transformed and averaged. For each comparison of interest
(Il10−/− versus C57 mice 7 weeks and Il10−/− versus C57
mice 12 weeks), a list of diﬀerentially expressed genes was
generated.
2.5. Quantitative RT-PCR. Quantitative RT-PCR (qRTPCR) has been described previously [17]. Ten genes (ATPbinding cassette subfamily B member 1, Abcb1A; aldehyde dehydrogenase 1 family member A1, Aldh1A1; carboxylesterase 2, Ces2; fatty acid binding protein 2, Fabp2;
insulin-like growth factor binding protein 5, Igfbp5; interleukin 1 beta, Il1B; matrix metallopeptidase 13, Mmp13;
Ppara, sterol regulatory element binding protein 1, Srebf1
and sulfotransferase family 1A phenol-preferring member
1, Sult1A1) were used for quantification and microarray
verification. Genes were selected to include both significantly
and non-significantly regulated genes pertaining to pathways
aﬀected by inflammation, for example, those related to
detoxification, transport, immunity, or metabolism. The
primer sequences for target and reference genes are available
upon request. The mRNA expression of all genes reported
was normalized to calnexin (Canx) gene expression.
2.6. Protein Isolation, LC-MS Analysis of Peptides, MS/MS
Data Processing, and Analysis. The protein-containing lower
layer of the same TRIzol processed sample from which
RNA was derived was used for protein isolation and further identification by liquid chromatography and tandem
mass spectrometry (LC-MS/MS). The protein pellets stored
in 0.3 M guadinine hydrochloride in 95% ethanol were
processed according to manufacturer’s instructions (TRIzol
protocol, Invitrogen) through two washes and a final ethanol
wash, and then allowed to air-dry. Resolubilization buﬀer
(7 M urea (BioRad), 2 M thiourea (Sigma), 4% CHAPS
(BioRad), 40 mM Tris (Invitrogen)) was added and samples
incubated at 22◦ C, 600 rpm, overnight in a Thermomixer
(Eppendorf). After centrifugation, supernatants were used
to determine protein concentration using the Bradford
protein assay with bovine serum albumin as a standard [21].
Volumes of samples that required pooling were calculated to
produce total aliquots of 50 μg per treatment. Gels were run
as duplicate biological replicates using the same samples as
described for the microarray design. The 50 μg total protein
of treatment and control samples were labeled with 200 pmol
of cyanine-2 and cyanine-5 dyes (GE Healthcare, Uppsala,
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Sweden), respectively, as described by the manufacturer. The
labeled treatment and control sample were combined to
make 100 μg protein and run on Immobiline Drystrips (GE
Healthcare, 18 cm, pH 3–11 nonlinear) in an equal volume
of 7 M urea, 2 M thiourea, 4% CHAPS, a few grains of
Bromophenol Blue (Sigma), 2% pH 3–11 NL IPG buﬀer
(GE Healthcare), and 65 mM DTT buﬀer (Sigma) to separate
the proteins in the first dimension. The first dimension,
equilibration, and second dimension were performed as
previously described [22]. Precision Plus protein standard
plugs (BioRad) were used as molecular weight markers.
Immediately after electrophoresis, the gels were washed
in double-distilled H2 O and visualized using a Typhoon
(TM) 9400 imager (GE Healthcare). The cyanine-2 images
were scanned using a 488 nm laser and a 520 nm band
pass 40 emission filter, whereas the cyanine-5 images were
scanned using a 633 nm laser and a 670 nm band pass 30
emission filter. All gels were scanned at a resolution of
200 μm, and analyzed using Phoretix 2D Evolution software
(Nonlinear Dynamics). Staining was performed by placing
gels into modified Neuhoﬀ colloidal Coomassie stain (17%
ammonium sulphate, 3% phosphoric acid, 34% methanol,
0.1% Coomassie G-250) [23], after which gels were dried
on glass plates at room temperature under cellophane and
stored.
Diﬀerentially expressed proteins were only flagged as
significant where the fold abundance for each biological
replicate changed in the same direction and either both gave
a value either < −1.5- or >1.5- fold, or where one biological
replicate gave a value <−2-or >2-fold and the other biological
replicate gave a value <−1.3 or >1.3. Significant protein spots
were excised from the dried gels, rehydrated in deionized
water, and digested with trypsin. Briefly, 25 mM ammonium
bicarbonate in 50% acetonitrile was added to the gel pieces
which were then incubated in a Thermomixer (1400 rpm,
22◦ C, 10 minutes) with up to two repeats of this step,
depending on the density of the original staining. The gel
pieces were then dried in a vacuum centrifuge (Speedyvac)
and rehydrated at room temperature in a trypsin/HCl mix
(20 μL trypsin of a stock made from 25 μg vial of Roche
modified trypsin (sequencing grade) in 50 μL 1 mM HCl
(BDH), 200 μL NH4 HCO3 (Sigma) pH 8.0, 10 μL 100%
acetonitrile (BDH)). Following overnight incubation in the
Thermomixer (37◦ C, 600 rpm), 30 μL of 5% formic acid
(Pierce) in 50% acetonitrile (Sigma) was added to the gel
pieces which were sonicated for 5 minutes. The samples
were briefly centrifuged and the supernatent removed which
was repeated twice. Two additional extractions in formic
acid/acetonitrile were repeated and pooled. Recovered peptides were concentrated by reducing the final volume of
the extracts to approximately 10 μL in a vacuum centrifuge,
followed by resuspension to a volume of 20 μL with formic
acid/acetonitrile. The peptide solutions were stored at −20◦ C
until MS was performed.
Tryptic peptides were separated and analyzed using
an Ettan multidimensional liquid chromatography system
(GE Healthcare) coupled to an LTQ linear ion trap mass
spectrometer with a nanospray ionisation interface (ThermoQuest, Finnigan, San Jose, CA, USA). Samples (2 μL)
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Table 1: Body weight and dietary intake of Il10−/− and C57 mice at 7, 8.5, 10, 12, and 14 weeks of age.

Weeks of age
7
8.5
10
12
14

Body weight (g)
C57 mice
18.8 ± 0.4
20.3 ± 0.9
22.5 ± 0.6
24.8 ± 0.7
25.3 ± 0.4

Dietary intake (g)
Il10−/− mice
18.2 ± 0.8
19.0 ± 0.3
19.9 ± 0.4∗
21.0 ± 0.8∗
19.8 ± 0.7∗

C57 mice
3.4 ± 0.1
3.6 ± 0.1
3.7 ± 0.0
3.6 ± 0.1
3.6 ± 0.1

Il10−/− mice
3.3 ± 0.2
3.9 ± 0.3
3.9 ± 0.1
3.5 ± 0.2
3.5 ± 0.3

Data shown as mean ± standard error of mean (SEM) per group of mice sacrificed. Body weight was measured thrice weekly and dietary intake was estimated
and adjusted daily to equal the mean amount of food consumed by Il10−/− mice on the previous day to ensure similar intakes between C57 and Il10−/− mice.
∗
P < 0.05 comparing Il10−/− versus C57 mice of the same age.

were injected onto a 300 μm ID × 5 mm trap column
(Zorbax 300-SB C18) for in-line desalting and separated on
a nanoscale reverse phase chromatography column 75 μm
ID × 150 mm, 3 μm (LC Packings, San Francisco, CA, USA)
in high-throughput configuration at 280 nL/minute with a
linear gradient from 0 to 60% B over 50 minutes (A: 0.1%
formic acid; B: 84% acetonitrile and 0.1% formic acid). Data
were acquired using a top 3 experiment in data-dependent
mode with dynamic exclusion enabled.
MS/MS data were analyzed using TurboSEQUEST protein identification software [24, 25] and spectra were
searched against the NCBI (National Center for Biotechnology Information) Mus musculus database. Modifications
were set to allow for the detection of oxidized methionine
(+16) and carboxyamidomethylated cysteine (+57). The
criteria used for a positive peptide identification for a doubly
charged peptide were a correlation factor (XCorr) >2.0,
a delta cross-correlation factor (dCn) >0.1 (indicating a
significant diﬀerence between the best match reported and
the next best match), and a high preliminary scoring (Sp).
For triply charged peptides the correlation factor threshold
was set at 2.5. All matched peptides were confirmed by visual
examination of the spectra.
2.7. Bioinformatics Analysis of Pathways and Functions.
IPA (Version 7.0, Ingenuity Systems Inc., Redwood City,
CA, USA) was used for pathway, network, and functional
analyses of diﬀerentially expressed probes in the microarray
dataset as described previously [17] and of diﬀerentially
expressed proteins. EASE (software version 2.0, National
Institutes of Health, USA) was used to identify enriched
biological themes within gene lists using GO category overrepresentation analysis [26]. A stringent set of gene probes
diﬀerentially expressed according to the microarray analysis
were uploaded into EASE along with a list of all genes on
the microarray to test for over-representation of annotation
classes. An EASE score (adjusted Fisher’s exact test for
statistical significance) was calculated for likelihood of overrepresentation of hierarchical categories based on biological
processes, molecular functions, and cellular components
using the GO public database. Gene categories with an EASE
score <0.05 and an FDR or q < 0.05 were considered to
be significantly over-represented. The data files containing
gene and protein identifiers (gene and protein accession

number) and the corresponding changes in expression levels
were uploaded into the IPA program. Genes and proteins
from the dataset that satisfied the cut-oﬀ criteria of FC ≥
1.5 (up- or down-regulated), FDR or q < 0.05, and FC
≥ 1.5, respectively, were considered for analyses. Pathways
were considered to be aﬀected by the development of colon
inflammation when the probability value calculated by the
Fisher’s exact test was <0.01 and where at least 20% of the
genes from a particular pathway were diﬀerentially expressed
in the microarray dataset.
2.8. Statistical Analysis. All statistical analyses (body weight,
dietary intake, HIS, and qRT-PCR data) were performed
using ANOVA in GenStat (10th edition, VSN International,
Hemel Hempstead, UK), on log-transformed data where
necessary in cases of unequal variances. A probability value
of less than 0.05 was considered as significant while a
probability value greater than 0.05 but lower than 0.10 was
considered a trend.

3. Results
3.1. Animal Body Weight and Dietary Intake. There was no
diﬀerence between Il10−/− and C57 mice in terms of average
body weight at the beginning of the experiment (16.5 ±
0.3 versus 16.9 ± 0.2 g, Table 1). During the course of the
experiment, Il10−/− mice gained weight more slowly (with
a loss in body weight observed between 12, and 14 weeks of
age) than C57 mice, resulting in a lower average body weight
at 7, 8.5, 10, 12, and 14 weeks of age when compared to
the C57 mice. This was significant (P < 0.05) at 10, 12, and
14 weeks of age. Dietary intake was not diﬀerent between
Il10−/− and C57 mice at any time point in the study (Table 1).
3.2. Development and Characterization of Intestinal Inflammation. Histological analysis showed that the average total
HIS in Il10−/− mice was highest in the colon, and only two
mice displayed moderate inflammation in the ileum. No
signs of inflammation were observed in the duodenum or
jejunum of Il10−/− mice or in any of the diﬀerent intestinal
sections of C57 mice (Figure 1). Therefore, statistical analysis
was performed on the colon tissue of Il10−/− mice. There was
a significant diﬀerence in the average total HIS in the colon
between Il10−/− and C57 mice at 8.5, 10, 12 and 14 weeks of
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Table 2: Time of onset and incidence of colon inflammation in
Il10−/− mice.
Weeks of age
Number of mice sampled
Il10−/− mice (total 281 )
C57 mice (total 30)
Number of mice with inflamed
colon2
Il10−/− mice
C57 mice
Incidence of colon inflammation (%)
Il10−/− mice
C57 mice

7

8.5

10

12

14

5
6

6
6

6
6

6
6

5
6

2
0

4
0

6
0

6
0

4
0

40
0

67
0

100 100
0
0

80
0

Two Il10−/− mice died during the study due to unknown causes. 2 Mice
were regarded as inflamed when their total colon histological injury score
(HIS) was >3 (4–6 moderate inflammation, ≥7 severe inflammation). All
C57 mice had a total colon HIS ≤ 3.
1

age. Two Il10−/− mice at 7 weeks of age showed initial signs of
colon inflammation, but not the other three mice (Table 2).
Most Il10−/− mice developed moderate colitis already by 8.5
weeks of age. It became apparent that the average total colon
HIS of Il10−/− mice increased over time peaking between 10
and 12 weeks of age, and a decrease between 12 and 14 weeks
of age.
Colitis was mainly characterized by inflammatory cell
infiltration (monocytes and neutrophils) but also featured
tissue destruction (crypt loss and oedema) and tissue repair
(hyperplasia). The colon of Il10−/− mice was highly inflamed
by 10 weeks of age and showed moderate inflammation
by 12 and 14 weeks of age (Figure 1). The total colon
HIS in 10-week-old Il10−/− mice was significantly higher
(P < 0.05) and a trend was observed at 12 weeks of age
(P = 0.07) compared to 7-week-old Il10−/− mice. There
was also less variability in the individual colon HIS at 8.5,
10, and 12 weeks compared to 7 and 14 weeks of age. The
inflammatory lesions were transmural involving most layers
of the intestinal wall. There was thickening of the mucosal
layer and formation of crypt abscesses with loss of goblet cells
(Figure 2).
3.3. Inflammation-Induced Changes in Expression Profiles.
Seven and 12 weeks of age were chosen to assess changes
in colon gene and protein expression because these two
time points represented no inflammation (7 weeks of age)
in most of the mice (two mice with signs of inflammation
were excluded) and moderate inflammation (12 weeks of
age) in Il10−/− mice. Pathway and network analysis using
IPA was conducted on the transcriptome and proteome
data. The transcriptome data were also subjected to GO
analysis using EASE to confirm and further support the IPA
analysis. As expected, at the gene level, more changes were
observed at 12 weeks than at 7 weeks of age in Il10−/− mice
compared to C57 mice of the same age, with genes mostly
being up-regulated at each time point in the colon of Il10−/−
mice. Those gene changes are illustrated in Figure 3 which

shows the genes over-represented in the EASE analysis when
comparing Il10−/− and C57 mice at 7 and 12 weeks of age.
The mean expression of selected genes obtained by qRT-PCR
mostly confirmed the changes in expression levels from the
microarray analysis. The changes in expression levels of Ces2,
Il1B, Igfbp5, and Srebf1 genes became significant in the colon
of 7-week-old and 12-week-old Il10−/− mice, respectively by
using the more sensitive qRT-PCR analysis (Table 3).
Only four consistent protein expression changes were
identified at 7 weeks of age in a direct comparison of Il10−/−
versus C57 mice across the pooled biological replicates (pool
1 and pool 2), with two decreased and two increased in
expression levels. Of these, only two met the threshold
criteria and were visible after staining for spot picking and
subsequent identification. At 12 weeks of age, 44 consistent
protein expression changes were observed in Il10−/− versus
C57 mice across the pooled biological replicates (pool 1 and
pool 2) with 22 decreased and 22 increased in expression
levels. Here, 42 protein expression changes met the threshold
criteria and were selected for subsequent identification. The
combined 44 spot-features identified over the two time
points represented 40 unique proteins (excluding multiple
isoforms due to post-translational modifications) and are
shown in the gel image depicted in Figure 4, and listed in
Table 4. In seven cases, two or more proteins or protein
isoforms were identified in the same 2D gel spot-feature.
Several of these biological functions and metabolic and
signaling pathways have previously been shown to be governed by PPARα after ligand-induced activation, including
fatty acid-, lipid and amino acid metabolism, cell cycle,
immune response, and cell death both in the small intestine
[27] and colon [17].
3.4. Gene Ontology, Network/Function, and Pathway Analysis
of Colonic Genes and Proteins of Il10−/− and C57 Mice at 7
Weeks of Age. Genes diﬀerentially expressed at 7 weeks in
the colon of Il10−/− compared to C57 mice were classified
into 1493 GO categories. Only 21 of these categories were
over-represented based on an EASE score <0.05 and q <
0.05; these are listed in Table 5. The EASE analysis of
gene expression indicated that several biological processes
were over-represented such as antigen presentation, carbohydrate, and lipid metabolism for energy utilization and
steroid metabolism. Over-represented functional categories
included MHC class II receptor activity. Most of the colonic
genes in these GO categories showed up-regulated expression
in Il10−/− compared to C57 mice at 7 weeks of age.
In IPA, 50 networks were generated from the genes
diﬀerentially expressed in the colon of Il10−/− mice relative
to C57 mice at 7 weeks of age. The themes of the five
highest scoring networks (P < 0.05 using Fisher’s exact
test) which encompassed the highest number of diﬀerentially
expressed genes in the transcriptome dataset were cancer,
cell cycle, growth, proliferation, and death and cell-mediated
immune response (Table 6). As there were only two proteins
(adenylate cyclase-associated protein 1 and glutamate dehydrogenase 1) that had lower abundance, and one protein
(peroxiredoxin) with higher abundance between Il10−/− and
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10
Total histology score jejunum

8
6
4
2
0

8
6
4
2

IL10 7 weeks

IL10 8.5 weeks

IL10 10 weeks

IL10 12 weeks

IL10 14 weeks

a

b

bc

a

IL10 8.5 weeks

IL10 10 weeks

IL10 12 weeks

IL10 14 weeks

(b)

10

10

8

Total histology score colon

6
4
2
0

8
6
4
2

(c)

C57 14 weeks

C57 12 weeks

C57 10 weeks

C57 8.5 weeks

IL10 14 weeks

IL10 12 weeks

IL10 10 weeks

IL10 8.5 weeks

IL10 7 weeks

C57 14 weeks

C57 12 weeks

C57 10 weeks

C57 8.5 weeks

C57 7 weeks

0
C57 7 weeks

Total histology score ileum

a

IL10 7 weeks

(a)

C57 14 weeks

C57 12 weeks

C57 10 weeks

C57 7 weeks

IL10 14 weeks

IL10 12 weeks

IL10 10 weeks

IL10 8.5 weeks

IL10 7 weeks

C57 14 weeks

C57 12 weeks

C57 10 weeks

C57 8.5 weeks

C57 7 weeks

0
C57 8.5 weeks

Total histology score duodenum

10

(d)

Figure 1: Total histological injury score for duodenum, jejunum, ileum, and colon sections of Il10−/− and C57 mice at 7, 8.5, 10, 12, and 14
weeks of age. The individual scores and the average score (—) of each sampling group are shown. Statistical analysis was performed only for
total colon HIS of Il10−/− mice and diﬀerent letters mean that total colon HIS diﬀers compared to 7-week-old Il10−/− mice (a, b, P < 0.05
and c, 0.05 < P < 0.1).

C57 mice (both at 7 weeks of age), no network analysis was
carried out for protein in IPA.
The most significantly regulated pathways in IPA containing most of the diﬀerentially expressed genes (20%)
included antigen presentation (MHC class II genes such
as Hla-Dm, Hla-Dq, and Hla-Dr members) and interferon
signaling pathway for which the expression levels of genes
were mostly increased (Table 7).
3.5. Gene Ontology, Network/Function, and Pathway Analysis
of Colonic Genes and Proteins of Il10 −/− and C57 Mice at
12 Weeks of Age. At 12 weeks, diﬀerentially expressed genes
were classified into 1570 GO categories and 32 of these
categories were significantly over-represented with an EASE

score <0.05 and q < 0.05 and are listed in Table 8.
Genes in biological process categories associated with defense
response to biotic (e.g., pathogen) stimulus or stress were
the most over-represented among the up-regulated genes,
followed by humoral and innate immune response and antigen presentation. Genes assigned to protein activation, such
as post-translational changes targeting membrane proteins,
were also over-represented, and were mostly up-regulated in
Il10−/− compared to C57 mice.
In IPA, 48 networks were generated from the colonic
genes diﬀerentially expressed in Il10−/− compared to C57
mice at 12 weeks of age. In Table 6, the top 3 biological functions for the most significant transcriptomic and proteomic
networks are shown. These transcriptomic and proteomic
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(a)

(b)

(c)

Figure 2: Hematoxylin-eosin-stained colon sections of Il10−/− and C57 mice. (a) Colon section (×20) from a non-inflamed C57 mouse at 12
weeks of age. (b) Colon section (×100) from an Il10−/− mouse at 7 weeks of age with no inflammation. (c) Moderate to severe inflamed colon
section (×40) from an Il10−/− mouse at 12 weeks of age. Lesions involve most of the colon section with mainly monocyte and neutrophil
infiltration (←), crypt abscesses, and loss of crypt and goblet cells ().

Table 3: Validation of gene expression results from microarray analysis using qRT-PCR.
Gene symbol

Abcb1A
Aldh1A1
Ces2
Fabp2
Igfbp5
Il1B
Mmp13
Ppara
Srebf1
Sult1A1

Fold change microarray
Il10−/− versus C57
Il10−/− versus C57
7 weeks
12 weeks
−3.4
−2.8
−1.5∗
−3.0
∗
−1.8
−3.1
−1.9
−5.6
−1.5∗
1.6∗
1.8∗
6.4
∗
1.0
1.8
−2.0
−1.7
1.0∗
1.0∗
−3.2
−3.1

Fold change qRT-PCR Canx
Il10−/− versus C57
Il10−/− versus C57
7 weeks
12 weeks
−5.2
−4.9
−1.5#
−3.4
−2.9
−5.6
−1.5#
−9.8
−1.9#
2.8
3.4
8.5
#
2.7
9.9
−5.6
−3.8
1.2#
1.8
−3.6
−3.3

Canx (calnexin) reference gene used to to normalize the data; ∗ microarray result was not significantly diﬀerent using moderated t-statistics and false discovery
rate (FDR) control in limma; genes that satisfied the criterion of FC ≥ 1.5 and q < 0.05 were considered to be significantly diﬀerent; # qRT-PCR result was not
significantly diﬀerent using ANOVA.

networks share the following biological functions: cellmediated immune response is represented in transcriptome
4 and proteome 1, cancer is represented in transcriptome
2 and proteome 3, and cell-to-cell signaling and interaction is represented in transcriptome 1 and 4. Thus, the
theme linking transcriptomic and proteomic networks is
cell migration and changes in tissue structure (implications
for actin cytoskeleton dynamics) as well as cell death with
associated inter- and intracellular signaling and initiation of
the immune response.
The most significantly regulated pathways in IPA featuring most of the diﬀerentially expressed genes (20–
40%) included signaling processes (Table 7). The signaling
pathways included antigen presentation pathway (MHC class

I, e.g., Hla members and MHC class II, e.g., Hla-Dm, Hla-Dq,
Hla-Dr members, genes); graft-versus-host disease signaling
and allograft rejection signaling (e.g., Il1B, Tnfa), interferon
signaling (e.g., Ifng), role of RNA-dependent protein kinase
(PKR) in interferon induction and antiviral response (e.g.,
Bcl), dendritic cell maturation and complement system, and
the genes in those pathways were mostly up-regulated.

4. Discussion
This study characterizes colitis onset and progression at
the histopathological, transcriptome, and proteome level in
bacterially inoculated Il10−/− mice (C57BL/6J background).
Here, we show that most Il10−/− mice developed moderate

gi|157951604
gi|6680027
gi|6671549

gi|6752954
gi|6671507
gi|6752954
gi|148666671
gi|6752954

gi|21312260

gi|160333304
gi|33563236

gi|6680748

gi|6680748

gi|31980648

gi|6753244
gi|145301561
gi|126521835
gi|6680924
gi|6680924

gi|6755522

gi|33859482
gi|123261836
gi|31712036
gi|14149635
gi|6680027
gi|123123547

7 weeks
1
2
3

12 weeks
4
5
6
7
8

9

10
11

12

13

14

15
16
17
18
19

20

21
22
23
24
25
26

actin, gamma, cytoplasmic 1
actin, alpha 2, smooth muscle, aorta
actin, gamma, cytoplasmic 1
actin, gamma 2, smooth muscle, enteric
actin, gamma, cytoplasmic 1
aldehyde dehydrogenase 1 family, member
B1
apolipoprotein A-I
Rho, GDP dissociation inhibitor (GDI) beta
ATP synthase, H+ transporting,
mitochondrial F1 complex, alpha subunit,
isoform 1
ATP synthase, H+ transporting,
mitochondrial F1 complex, alpha subunit,
isoform 1
ATP synthase, H+ transporting
mitochondrial F1 complex, beta subunit
calmodulin 1
carbonic anhydrase 1
chaperonin subunit 2 (beta)
cofilin 1, non-muscle
cofilin 1, non-muscle
evolutionarily conserved signalling
intermediate in Toll pathway
eukaryotic translation elongation factor 2
EF hand domain containing 2
eukaryotic translation initiation factor 5A
fatty acid binding protein 4, adipocyte
glutamate dehydrogenase 1
gelsolin

CAP, adenylate cyclase-associated protein 1
glutamate dehydrogenase 1
peroxiredoxin 6

Accession number Protein description

Spot

Eef2
Efhd2
Eif5a
Fabp4
Glud1
Gsn

Ecsit

Calm1
Car1
Cct2
Cfl1
Cfl1

Atp5b

Atp5a1

Atp5a1

Apoa1
Arhgdib

Aldh1b1

Actg1
Acta2
Actg1
Actg2
Actg1

Cap1
Glud1
Prdx6

Gene (MGI)

95.3
26.8
16.8
14.6
61.3
85.9

49.7

16.8
28.3
57.4
18.5
18.5

56.3

59.7

59.7

30.6
22.8

57.5

41.8
42.0
41.8
41.9
41.8

51.5
61.3
24.8

Theoretical
Mr (kDa)

6.30
4.92
4.94
8.74
7.96
5.78

6.14

3.93
6.49
5.96
8.20
8.20

5.07

9.53

9.53

5.57
4.80

6.61

5.20
5.12
5.20
5.20
5.20

7.29
7.96
5.96

Theoretical
pI

10
5
3
5
10
5

2

3
7
11
4
4

16

12

15

4
4

8

10
3
9
4
6

2
3
5

No. peptides
matched

13.4
24.2
20.8
48.5
20.1
10.4

4.1

32.9
36.4
26.7
18.8
18.8

41.8

27.8

35.1

16.7
22.5

16.6

38.9
13.3
30.7
20.7
15.7

4.2
6.1
27.2

Sequence
coverage %

Table 4: Proteins diﬀerentially expressed in the colon of Il10−/− mice compared to C57 mice at 7 and 12 weeks of age.

8.98E-12
3.42E-08
9.81E-12
1.28E-08
7.64E-11
5.61E-07

1.54E-05

6.21E-11
4.32E-10
2.76E-09
8.89E-09
1.28E-09

5.47E-12

1.72E-12

3.40E-12

5.56E-12
4.11E-13

2.88E-09

7.54E-12
2.13E-06
2.76E-10
1.50E-06
7.93E-07

9.50E-05
2.85E-10
3.99E-08

SEQUEST P
(pro)

2.0
2.2
2.9
−2.9
−2.3

−5.8

−2.3

5.0
2.3
−2.2
2.9
2.5

−2.1

−2.1

−2.0

2.4
2.9

−3.3

−2.9

−7.4

−7.4

−3.2

−3.2

3.4

−2.9

−2.9

Fold change
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Hint1

Myl6
Pfn1
Rsp12
S100a4
S100a9

keratin complex 1, acidic, gene 19

heat shock protein 1, beta

heat shock protein 1, beta

mitochondrial ATP-dependent protease Lon

PREDICTED: similar to non-muscle myosin
alkali light chain

profilin 1

PREDICTED: similar to 40S ribosomal
protein S12

S100 calcium binding protein A4

S100 calcium binding protein A9
(calgranulin B)

stress-induced phosphoprotein 1

sorting nexin 6

triosephosphate isomerase 1

tubulin, alpha 1C

tubulin, beta 5

thioredoxin

villin 1

villin 1

villin 2

villin 2

gi|123236748

gi|40556608

gi|40556608

gi|26984237

gi|149266035

gi|6755040

gi|51772387

gi|33859624

gi|6677837

gi|18314646

gi|18314646

gi|14389431

gi|27754031

gi|226958349

gi|6678469

gi|7106439

gi|123210316

gi|148877507

gi|148877507

gi|83921618

gi|83921618

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

S100 calcium binding protein A11
(calgizzarin)
S100 calcium binding protein A11
(calgizzarin)

Lonp1

keratin complex 1, acidic, gene 19

gi|123236748

32

Krt8

keratin complex 1, acidic, gene 19

Vil2

Vil2

Vil1

Vil1

Txn

Tubb5

Tuba1c

Tpi1

Sx6

Stip1

S100a11

S100a11

Hsp90ab1

Hsp90ab1

Krt19

Krt19

Krt19

keratin complex 2, basic, gene 8

Igkv1-117

gi|114145561

gi|62024583

29

gi|123236748

histidine triad nucleotide binding protein

Cr1 protein

gi|56238582

28

Gsn

30

gelsolin

gi|123123547

27

Gene (MGI)

31

Accession number Protein description

Spot

69.4

69.4

92.7

92.7

11.7

49.7

50.1

26.7

45.0

62.5

11.1

11.1

13.0

11.7

14.5

15.0

13.0

10.6

83.2

83.2

44.5

44.5

44.5

54.5

26.3

13.8

85.9

Theoretical
Mr (kDa)

Table 4: Continued.

5.76

5.76

5.66

5.66

4.64

4.64

4.83

7.07

5.47

6.39

5.15

5.15

6.76

5.07

6.94

8.43

4.42

6.20

4.82

4.82

5.15

5.15

5.15

5.59

7.97

6.41

5.78

Theoretical
pI

8

7

20

13

4

9

12

3

3

7

1

1

4

2

2

6

3

4

17

15

9

13

6

16

2

2

3

No. peptides
matched

15.9

14.8

26.4

18.7

31.4

34.7

34.5

19.3

7.14

11.6

16.3

16.3

36.3

17.8

12.1

55.7

34.5

4.0

25.3

22.1

25.3

45.4

12.9

39.6

11.3

16.7

4.4

Sequence
coverage %

1.99E-08

3.15E-09

4.52E-08

8.57E-09

4.27E-07

1.30E-11

1.26E-11

6.59E-09

2.62E-05

1.31E-05

3.53E-05

1.65E-04

7.54E-06

1.43E-04

4.18E-04

1.42E-12

7.28E-06

5.94E-05

1.01E-11

2.47E-10

8.96E-10

1.82E-08

6.39E-10

1.20E-11

2.05E-09

1.39E-10

2.19E-07

SEQUEST P
(pro)

−2.6

−2.4

−4.6

−3.2

2.5

−2.2

−2.0

2.1

−2.3

−3.9

3.2

5.1

4.0

2.4

2.1

2.9

5.1

−3.0

−2.1

−2.8

−2.9

−7.4

−3.2

−2.0

2.2

2.1

−2.5

Fold change
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Ccl5
Ltb
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Ceacam12
Igj
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Ptprc
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Cd79b
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F3
Eef 2
Ccnk
Snrpb
Sema7a
Slpi
Igk-V21
Ly zs
C1s
H2-Aa
Clec7a
H2-Ab1
Pla2g5
Il1b
Ccnd2
Thbd
Ef nb2
Selp
Cy p4f 14
Car2
Wf dc2
Aqp4
Il18
Atp1b1
Hoxa9
Ctsh
Igh-6
Rbp1
Igf bp5
Rtn4
Sp5
C1qr1
Rgs2
Colec12
Hspa8
Thy 1
Gzma
C3
C2
Slc6a8
Mogat1
Apoe
C1r
Col1a1
C4
Hoxa10
Hoxa11
Lzp-s
Col18a1
Prg1
Hp
Akp2
Cxcl14
Cf h
Clu
Cp

Significantly expressed genes in significant gene ontology categories

Value

Figure 3: Genes over-represented in EASE analysis comparing Il10−/− and C57 mice at 7 or 12 weeks of age. Heat map represents the
expression levels of all diﬀerentially expressed genes in the significant GO categories (EASE score <0.05 and q < 0.05). The groups are clearly
defined within their clusters and diﬀerences in gene expression are seen for 12-week-old Il10−/− mice relative to 7-week-old Il10−/− mice and
12-week-old C57 mice.

colitis already by 8.5 weeks of age and severe colitis peaking
between 10 and 12 weeks of age when compared to 7-weekold Il10−/− mice. The nature of colon inflammation was similar to that displayed by conventionally housed Il10−/− mice
on the same genetic background not subjected to bacterial
inoculation and represented features characteristic of human
CD [16]. Several aspects of innate and adaptive immune
responses were aﬀected at the gene expression level before

(7 weeks of age) and after (12 weeks of age) colitis onset
in Il10−/− mice. These findings agree with the inflammatory
and immune responses observed in CD patients who have a
defective interaction between their innate mucosal immune
system and luminal bacteria [28]. This study focuses on
those pathways linking the gene and protein expression
changes such as cytoskeletal rearrangement, cell migration,
and innate immunity that underlie colitis development in
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Figure 4: 2D-DIGE gel representing diﬀerentially expressed proteins identified in the colon tissue of Il10−/− mice compared to C57 mice at
7 and 12 weeks of age, respectively. Protein annotations are shown in Table 4. The approximate isoelectric point (pI) and molecular weight
(MW) in kDa are given on the x- and y-axes, respectively.

Table 5: Categories of genes with expression increase of 2-fold or more in Il10−/− mice compared to C57 mice at 7 weeks of age using EASE.
System

Gene category

EASE score

FDR

GO Cellular Component

spindle cell

3.91E-04

<0.001

GO Molecular Function

MHC class II receptor activity

1.25E-03

<0.001

GO Biological Process

antigen processing, exogenous antigen via MHC class II

1.37E-03

<0.001

GO Biological Process

antigen presentation, exogenous antigen

1.37E-03

<0.001

GO Biological Process

alcohol metabolism

2.27E-03

<0.001

GO Biological Process

glucose metabolism

4.37E-03

<0.001

GO Biological Process

main pathways of carbohydrate metabolism

6.39E-03

<0.001

GO Biological Process

protein targeting

7.76E-03

<0.001

GO Biological Process

steroid biosynthesis

1.02E-02

<0.001

GO Biological Process

steroid metabolism

1.09E-02

<0.001

GO Biological Process

sterol biosynthesis

1.29E-02

<0.001

GO Cellular Component

microtubule cytoskeleton

1.75E-02

<0.001

GO Biological Process

sterol metabolism

1.82E-02

<0.001

GO Biological Process

carbohydrate metabolism

1.89E-02

<0.001

GO Biological Process

hexose metabolism

1.92E-02

<0.001

GO Molecular Function

oxidoreductase activity, acting on CH-OH group of donors

1.96E-02

<0.001

GO Biological Process

energy derivation by oxidation of organic compounds

2.47E-02

<0.001

GO Biological Process

catabolism

2.54E-02

<0.001

GO Cellular Component

soluble fraction
oxidoreductase activity, acting on the CH-OH group of donors, NAD or
NADP as acceptor

2.82E-02

<0.001

2.92E-02

<0.001

monosaccharide metabolism

3.13E-02

<0.001

GO Molecular Function
GO Biological Process
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Table 6: Proteome and transcriptome network analysis for expression profiles from the colon of 7- and 12-week-old Il10−/− mice compared
to C57 mice using IPA.
Network
Top functional categories
−/ −
Il10
versus C57 mice at 7 weeks of age
Transcriptome 1
Cancer, Dermatological disease and conditions, Endocrine system development and function
Transcriptome 2
Cardiovascular system development and function, Cancer, Tissue development
Transcriptome 3
Cancer, Cell death, Reproductive system disease
Transcriptome 4
Cell cycle, Cell-mediated immune response, Cancer
Transcriptome 5
Cellular growth and proliferation, Hematological system development and function, Hematopoiesis
Il10−/− versus C57 mice at 12 weeks of age
Proteome 1
Tissue morphology, Cellular movement, Cell-mediated immune response
Proteome 2
Cell death, Hematological disease, Immunological disease
Proteome 3
Cancer, Tumour morphology, Cellular development
Proteome 4
Cardiovascular disease, Gene expression, Molecular transport
Transcriptome 1
Antigen presentation, Cell morphology, Cell-to-cell signaling and interaction
Transcriptome 2
Cancer, Gastrointestinal disease, Dermatological diseases and conditions
Transcriptome 3
Lipid metabolism, Small molecule biochemistry, Carbohydrate metabolism
Transcriptome 4
Inflammatory disease, Cell-to-cell signaling and interaction, Cell-mediated immune response
The top 3 biological functions for the most significant transcriptomic and proteomic networks (representing subsets of focus genes and proteins highly
associated with those functions) are shown.

this Il10−/− mouse model. Since PPARα has previously been
identified as a potential key mediator in inflammation [17],
the findings of this study showed that Ppara is involved in
signaling processes before and after colitis onset likely to
control colitis. Further, a potential link between PPARα and
IL10 is suggested.
4.1. Change in Transcriptomic Profile with Colitis. Increased
expression levels of membrane-bound Tlr2 and Tlr9 genes
in the colon of 12-week-old Il10−/− compared to C57 mice
were consistent with their reported function. Peptidoglycan
and lipoproteins from the cell wall of commensal bacteria are
recognized by TLR2 [28]. The underlying abnormal response
between the innate immune system to bacterial structures
is mediated via TLR and other pattern-recognition receptors which then regulate antigen-specific adaptive immune
responses [29]. Dendritic cells, an important cellular component of the mucosal innate immune system, sample intestinal
bacteria through pattern recognition with TLR [30]. The
recognition of bacterial structures by TLR2 can lead to
activation of NFκB-MAPK pathways and interferon regulatory factor family members [31]. This activation in turn
induces diﬀerentiation of cells producing pro-inflammatory
cytokines, such as IFNγ and IL17, responsible for CD-like
inflammation [28]. Increased mRNA abundance of the Tlr9
gene in 7-week and 12-week-old Il10−/− mice compared to
C57 mice may be associated with signaling events in order
to maintain or reestablish colonic homeostasis, respectively.
Lee et al. [31] reported distinct transcriptional responses
of TLR9 activation through apical and basolateral surface
domains to maintain colonic homeostasis and regulate
tolerance and inflammation. Basolateral TLR9 activation of
intestinal epithelial cells leads to NFκB signaling, whereas
apical TLR9 stimulation prevented NFκB activation. These

TLR-dependent innate immune responses seemed to be
important in the Il10−/− mouse colitis model in order to
adapt to luminal bacteria and their antigens.
The gene network analysis in our previous study linked
genes involved in inflammatory and immune response,
tryptophan and xenobiotic metabolism, and antigen presentation [17]. Several genes of these pathways were also
diﬀerentially expressed mostly in the 12-week-old Il10−/−
mice. The higher expression levels of MHC class I and class
II genes in the colon of Il10−/− compared to C57 mice
at 12 weeks were likely to be associated with mounting
antigen-specific adaptive immune responses to bacterial
invasion. The expression level of Ido1, a gene involved in
tryptophan catabolism, was increased at both 7 and 12 weeks
of age in colitic Il10−/− mice. High expression level of the
anti-inflammatory enzyme IDO was observed in intestinal
biopsies from CD patients [32]. The pro-inflammatory
cytokine genes Ifng and Tnfa, known as potent inducers of
INDO protein activity [33], had higher mRNA abundance
only in the inflamed colon of 12-week-old Il10−/− mice.
Elevated levels of IL10 and TGFB have also been found in
CD patients, and it was suggested that this modulated the
immune response and caused activation of B lymphocytes
[32]. The increased expression levels of tryptophan (e.g.,
Ido1) and antigen presentation (e.g., Hla class II members)
genes in the 12-week-old Il10−/− mice might be linked to
the restoration of tolerance towards bacterial antigens. In
7-week-old non-inflamed Il10−/− mice, increased Ido1 gene
expression might also be important in the early response to
commensal bacteria preceding colitis due to the deficiency of
the Il10 gene. Increased mRNA abundance of genes involved
in the complement activation, antigen presentation, and Bcell receptor signaling in 12-week-old Il10−/− mice is in
agreement with functional implications of PPARα activation.
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Table 7: Diﬀerentially expressed genes in the colon of Il10−/− mice compared to C57 mice at 7 and 12 weeks of age.
Gene symbol

Gene name

GenBank
accession

Il10−/− versus C57
7 weeks of age

Il10−/− versus C57
12 weeks of age

FC

FDR

FC

FDR

0.315

−1.6

0.02

Actg2

actin, gamma 2, smooth muscle, enteric

NM 007392

−1.3

Arhgap12

Rho GTPase activating protein 12

NM 029277

−1.1

0.549

−1.5

<0.001

Arhgdib

Rho GDP dissociation inhibitor (GDI) beta
Rho guanine nucleotide exchange factor (GEF)
10-like

NM 007486

1.1

0.562

2.0

<0.001

AK028648

2.4

<0.001

2.3

<0.001

Bcl2A1

BCL2-related protein A1

NM 007534

1.6

0.001

2.7

<0.001

Bcl3

B-cell CLL/lymphoma 3
complement component 1, q subcomponent, A
chain
complement component 1, q subcomponent, C
chain

NM 033601

1.6

0.044

1.7

0.015

NM 007572

1.1

0.67

1.6

0.003

NM 007574

1.3

0.29

1.8

0.005

Arhgef10L

C1Qa
C1Qc
C1R

complement component 1, r subcomponent

NM 023143

1.5

0.018

2.0

<0.001

C1S

complement component 1, s subcomponent

NM 144938

1.3

0.059

1.9

<0.001

C2

complement component 2

NM 013484

1.2

0.337

2.6

<0.001

C3

complement component 3

NM 009778

1.8

0.015

4.5

<0.001

C4B

complement component 4B (Chido blood group)

NM 009780

−1.0

0.976

1.6

0.005

Ccl5

chemokine (C-C-motif) ligand 5 (Rantes)
CD74 molecule, major histocompatibility
complex, class II invariant chain

NM 013653

1.1

0.7

2.3

<0.001

NM 010545

4.0

<0.001

5.5

<0.001

<0.001

Cd74
Fas

Fas (TNF receptor superfamily, member 6)

NM 007987

1.9

1.5

<0.001

Gsn

gelsolin

NM 146120

−1.8

0.006

−2.0

<0.001

Hla-A

major histocompatibility complex, class I, A

NM 010391

1.4

0.201

2.3

<0.001

Hla-B

major histocompatibility complex, class I, B

NM 008199

−1.4

0.104

1.9

<0.001

Hla-C

major histocompatibility complex, class I, C
major histocompatibility complex, class II, DM
alpha
major histocompatibility complex, class II, DM
beta
major histocompatibility complex, class II, DQ
alpha 1
major histocompatibility complex, class II, DQ
beta 2
major histocompatibility complex, class II, DR
beta 1

NM 010380

1.4

0.005

2.3

<0.001

NM 010386

1.5

<0.001

2.1

<0.001

NM 010387

4.9

<0.001

6.6

<0.001

NM 010378

1.8

<0.001

2.9

<0.001

NM 010379

3.1

<0.001

5.3

<0.001

NM 010382

2.5

<0.001

4.5

<0.001

NM 013819

1.4

0.013

2.0

<0.001

NM 008255

1.7

0.005

1.5

0.005

Hla-Dma
Hla-Dmb
Hla-Dqa1
Hla-Dqb2
Hla-Drb1
Hla-G
Hmgcr

major histocompatibility complex, class I, G
3-hydroxy-3-methylglutaryl-Coenzyme A
reductase

Ido1(Indo)

indoleamine 2,3-dioxygenase 1

NM 008324

6.6

<0.001

8.1

<0.001

Ifng

interferon, gamma

NM 008337

1.4

0.071

1.7

0.003

Il1B

interleukin 1, beta

NM 008361

1.8

0.211

6.4

<0.001

Il1Rn

interleukin 1 receptor antagonist

NM 031167

1.3

0.442

1.8

0.024

Il10

interleukin 10

NM 010548

1.1

0.461

1.1

0.421

Mapk13

mitogen-activated protein kinase 13

NM 011950

1.8

<0.001

1.7

<0.001

Mapk9

mitogen-activated protein kinase 9
nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha

NM 016961

1.5

0.004

1.6

<0.001

NM 010907

1.6

0.002

1.6

0.001

Nfkbia
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Table 7: Continued.

Gene symbol

Gene name

GenBank
accession

Il10−/− versus C57
7 weeks of age
FC

Nfkbie
Ppara
Ppargc1A

nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, epsilon
peroxisome proliferator-activated receptor alpha
peroxisome proliferator-activated receptor
gamma, coactivator 1 alpha

FDR
0.001

Il10−/− versus C57
12 weeks of age
FC
1.7

FDR
<0.001

NM 008690

1.5

NM 011144

−2.0

<0.001

−1.7

0.001

NM 008904

−1.7

0.008

−1.4

0.052

Tlr2

toll-like receptor 2

NM 011905

1.1

0.857

1.9

0.001

Tlr9

toll-like receptor 9
tumour necrosis factor (TNF superfamily,
member 2)
tumour necrosis factor receptor superfamily,
member 1B

NM 031178

1.9

<0.001

1.9

<0.001

NM 013693

1.3

0.064

1.7

<0.001

NM 011610

1.3

0.115

1.5

0.003

thioredoxin

NM 011660

−1.2

0.494

−1.0

0.932

Tnf
Tnfrsf1B
Txn

Genes were grouped into one or more of the following IPA pathways: antigen presentation, graft versus host disease signaling, allograft rejection signaling,
interferon signaling, role of PKR in interferon induction and antiviral response, dendritic cell maturation, complement system, endoplasmic reticulum stress,
and steroid metabolism. Genes with fold change (FC) ≥1.5 and false discovery rate (FDR) or q < 0.05 were considered for pathway analysis.

PPARα has been associated with the innate immune response
of the small intestine using Ppara−/− and wildtype mice, and
its pharmacological activation inhibited complement activation, antigen presentation, and B-cell receptor signaling [27].
4.2. Change in Proteomic Profile with Colitis. Proteins diﬀerentially expressed in inflamed Il10−/− mice were involved in
cytoskeletal rearrangement, cell-mediated immune response,
and pathogen-influenced signaling. The cytoplasmic actin
gamma 1 and smooth muscle actin gamma 2 proteins
(ACTG1 and ACTG2) were less abundant in the colon
of Il10−/− compared to C57 mice at 12 weeks of age.
Pro-inflammatory cytokines and bacteria can modify tight
junctions interconnecting intestinal epithelial cells via the
actin cytoskeleton so disruption of actin leads to disruption
of tight junctions and loss of barrier function with increased
paracellular permeability [34]. This is further supported by
a study reporting decreased actin-binding gene expression
levels in peripheral blood mononuclear cells of IBD patients
suggesting that disruption of the actin cytoskeleton might
contribute to CD pathogenesis in humans [35]. The ACTG2
protein was also decreased in expression at the gene level
in the 12-week-old Il10−/− mice compared with C57 mice,
but the Actg2 gene remained unchanged in Il10−/− mice at 7
weeks of age when the intestinal barrier was presumably still
intact.
Actin-binding proteins including gelsolin (GSN)
involved in the regulation of actin-based motility by
calcium-dependent Rho-family GTPases (e.g., RhoA, Rac1
and Cdc42) were diﬀerentially expressed in the colon
of Il10−/− mice at 12 weeks of age. Rho-family proteins
share growth-promoting and anti-apoptotic functions,
regulation of gene expression through activation of signaling
molecules, for example, NFκB [36]. They can promote actin

cytoskeleton reorganization, but Rho-family proteins diﬀer
in their eﬀect on cell movement; for example, RhoA induces
the formation of stress fibers and focal adhesions [36]. Rho
GDP dissociation inhibitor (GDI) beta (Rho GDIβ) protein,
which is encoded by the Arhgdib gene (mRNA abundance
was increased in 12-week-old Il10−/− mice), regulates
RhoGTPase activity by inhibiting GDP dissociation to leave
RhoGTPases inactive [37]. This suggests that in the inflamed
colon of those Il10−/− mice, Rho protein activity is being
inhibited by Rho GDIβ and thus inhibits actin cytoskeleton
reorganization. Enhanced T-cell migration as a consequence
of the inflammatory state of the intestine is maintained by
pro-inflammatory cytokines and has been associated with
increased expression levels of GSN protein in smooth muscle
cells in the small intestine of CD patients [38]. However, the
expression level of GSN protein and Gsn gene was reduced
in the colon of 12-week-old Il10−/− mice which might reflect
a declining inflammatory cell movement. This is supported
by the decreased inflammatory lesions in the colon of
Il10−/− mice from 12 weeks to 14 weeks of age and might
be associated with reduced inflammatory cell migration.
Gelsolin-null mice have shown reduced neutrophil and
fibroblast movement [39].
The actin cytoskeleton is a flexible system that is built
up or broken down depending on antigen recognition, cell
polarization, and cell adhesion or cell migration. Actinbinding proteins are involved in surface receptor clustering
during T-cell activation and migration to dynamic cytoskeletal rearrangements at the interface between T-cells and
antigen presenting cells [40]. A study using an in vitro
model of simulated ischemia-reperfusion showed an involvement of Rho-kinase-dependent cytoskeletal rearrangement
in apoptosis initiation [41]. In the colon of the 12-weekold Il10−/− mice, Rho GDIβ may have inhibited or delayed
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Table 8: Categories of genes with expression increase of 2-fold or more in Il10−/− mice compared to C57 mice at 12 weeks of age using EASE.
System
GO Biological Process
GO Biological Process
GO Biological Process
GO Biological Process
GO Biological Process
GO Biological Process
GO Molecular Function
GO Molecular Function
GO Biological Process
GO Biological Process
GO Molecular Function
GO Biological Process
GO Biological Process
GO Molecular Function
GO Biological Process
GO Biological Process
GO Cellular Component
GO Biological Process
GO Biological Process
GO Cellular Component
GO Biological Process
GO Biological Process
GO Molecular Function
GO Molecular Function
GO Molecular Function
GO Biological Process
GO Biological Process
GO Biological Process
GO Cellular Component
GO Biological Process
GO Biological Process

Gene category
defence response
response to biotic stimulus
response to external stimulus
immune response
antigen presentation
antigen processing
defence/immunity protein activity
MHC class I receptor activity
response to pest/pathogen/parasite
physiological process
antigen binding
response to stress
antigen presentation, endogenous antigen
MHC class II receptor activity
antigen processing, exogenous antigen via MHC
class II
antigen presentation, exogenous antigen
extracellular space
protein targeting
humoral immune response
plasma membrane
antigen processing, endogenous antigen via MHC
class I
response to wounding
oxidoreductase activity, acting on CH-OH group
of donors
oxidoreductase activity, acting on the CH-OH
group of donors, NAD or NADP as acceptor
hydrolase activity
collagen catabolism
posttranslational membrane targeting
innate immune response
vesicular fraction
response to chemical substance
inflammatory response

actin rearrangement, and in part attenuated apoptosis, antiapoptosis genes such as Bcl2A1 gene was increased in expression. BCL3, a component of the cellular cytokine-induced
inflammatory signaling cascade, has been shown to interact
cooperatively with PPARGC1α to activate estrogen-related
receptors and PPARα resulting in increased expression of
target genes involved in cellular energy metabolism [42].
Although Bcl3 mRNA abundance was increased, Ppara and
Ppargc1a gene expression levels decreased in 7-week, and 12week-old Il10−/− mice which imply an impaired energetic
adaptation of the colonocytes to bacterial- or cytokineinduced cellular stress at an early and late stage, respectively.
This is supported by findings from others that the failure
of regulatory mechanism in Il10−/− mice under developing

EASE score
5.92E-14
7.39E-14
1.38E-12
4.06E-12
4.14E-07
4.52E-06
6.14E-06
2.67E-05
1.43E-04
1.47E-04
2.31E-04
2.49E-04
1.21E-03
1.56E-03

FDR
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

1.67E-03

<0.001

1.67E-03
1.75E-03
2.57E-03
2.97E-03
7.23E-03

<0.001
<0.001
<0.001
<0.001
<0.001

8.44E-03

<0.001

1.07E-02

<0.001

1.15E-02

<0.001

1.71E-02

<0.001

1.86E-02
2.07E-02
2.18E-02
2.22E-02
2.51E-02
3.06E-02
3.06E-02

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

colitis primes the epithelium towards energy deficiency and
uncontroled cellular stress leading to tissue damage [15].
IL10 and also PPARα seem to be important in this regulatory
mechanism.
The thioredoxin (TXN) protein, known to function
as an antioxidant in the maintenance of cellular redox
homeostasis, was more highly expressed in 12-week-old
Il10−/− mice compared with C57 mice. Thioredoxin has
previously been identified as a PPARα target gene and a
negative autoregulation of PPARα activity by thioredoxin
was suggested as a novel mechanism for controling PPARα
activities and PPARα-related physiological or pathological
processes [43]. The finding of the present study may also be
explained by a functional down-regulation of normal PPARα

16
activities such as lipid and inflammatory regulation through
the thioredoxin-mediated negative autoregulation of PPARα
transcriptional activity.
4.3. Il10−/− Colitis Model and PPARα Signaling. Several of
the gene expression changes in colitic Il10−/− mice at 12
weeks of age were related to PPARα signaling. A regulatory
role for PPARα in inflammation was first shown by the
prolonged duration of inflammation in Ppara−/− mice [18],
and network analysis identified Ppara as a key mediator gene
decreased in expression during colitis in Il10−/− compared to
C57 mice [17]. Furthermore, PPARα and also PPARγ ligands
exerted anti-inflammatory eﬀects in inflammatory disease
models. For example, administration of PPARα (bezafibrate) and PPARγ (troglitazone) ligands reduced dextran
sulphate sodium-induced colitis and cell proliferation in
colonic mucosa [19], PPARα ligand fenofibrate decreased
expression levels of pro-inflammatory Ifng and Il17 genes
in Il10−/− mice [20], PPARγ ligand rosiglitazone delayed
colitis onset in Il10−/− mice [7], and fenofibrate prevented
the progression of autoimmune myocarditis in rats through
increased cardiac Il10 mRNA levels [44].
PPARα is expressed in colonic immune and epithelial
cells where it acts in an anti-inflammatory manner upon
activation by a PPARα ligand [20]. In the present study, the
expression level of the Ppara gene was decreased in inflamed
and non-inflamed colons of Il10−/− mice when compared
to C57 mice without exogenous ligand-mediated PPARα
activation. It is known that PPARα governs inflammation
mainly by down-regulating gene expression such as acute
phase response genes [45]. PPARα (mRNA and protein)
expression levels were decreased in colorectal cancer in
the APC Min /+ mouse model of familial adenomatous polyposis compared with matched non-malignant tissue [46].
Ppara−/− mice show enhanced susceptibility dinitrobenzene sulfonate (DNBS)-induced colitis [47]. PPARα ligands
reduce colitis in chemically induced and genetic (including
Il10−/− mice) models of colitis [19, 20], whereas the absence
of PPARα abolishes the protective eﬀect of the PPARα ligand
WY14643 in DNBS-induced colitis [47]. Thus, activation of
PPARα appears to be a target for controling colitis including
in this inoculated Il10−/− mouse model. The decreased Ppara
gene expression level in 7-week-old Il10−/− mice suggests
that immune cells might have been activated due to increased
bacterial invasion and a lack of regulatory mechanisms
through Il10 gene deficiency, even though histopathological
signs of colitis were not clearly evident yet. It has been
reported that PPARα expression in murine lymphocytes is
rapidly decreased following T-cell activation suggesting a role
for PPARα in immune cells [48].
The anti-inflammatory eﬀect of fenofibrate by delaying
colitis onset and progression in Il10−/− mice indicates that
IL10 is not required in PPARα signaling [20]. In contrast,
another study emphasized the stimulation of the IL10 pathway in rats treated with fenofibrate to suppress myocarditis
[44]. This implicates a potential PPARα-dependent regulation of IL10. So far, it has been shown that rosiglitazone
induced IL10 production from human mature dendritic cells
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and CD4+ T-cells [49]. This eﬀect was PPARγ-dependent
due to a functional PPAR response element for PPARγ in the
human IL10 promoter region.
In conclusion, the findings from this study identified
distinct colonic gene and protein expression profiles for 7and 12-week-old Il10−/− mice. Gene and protein expression
data linked actin cytoskeleton dynamics, innate immunity,
and apoptosis and suggested a delayed remodeling process in
the colitic Il10−/− mice. PPARα might be one of the key mediators in these signaling processes before and after colitis onset
in Il10−/− mice. Ligand-mediated PPARα activation and IL10
production may be important for the anti-inflammatory
eﬀects of PPARα observed in inflammatory disease models
and possibly in the resolution of inflammatory disease in
humans. Confirmation of a role for PPARα activation in
intestinal IL10 production, and clarification of the mechanism by which this occurs, warrants further investigation.
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